Skip to Main Content

Paper Details

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Cancer Cell
116
2015
CHZ868, JAK, JAK inhibitor persistent cells, JAK2, JAK2 and MPL mutant, JAK2 and MPL mutant cell lines, MPL mutant, MPN, MPN cells, Myeloproliferative Neoplasms, mutant allele, myeloproliferative neoplasm, patient, patients, splenomegaly, type, type I JAK inhibitor persistent cells, type II JAK
Author NameAffiliation
Nicholas D SocciCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Agnes VialeCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
William R SellersNovartis Institutes for Biomedical Research
  • 1 - 3

Datasets

Release 1.2